Cancer immunotherapy candidate provokes powerful dual response in cancer and immune cells

Cancer immunotherapy drugs called PD-1 inhibitors are widely used to stimulate the immune system to fight cancer, but many patients either don’t respond or develop resistance to them. A new small-molecule drug candidate being tested in an early-stage clinical trial aims to improve patient responses to immunotherapy.

Leave A Comment

Your email address will not be published. Required fields are marked *